Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)		 Bcl-2 [1]
(Cell-free assay)		 Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NY\DUWlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHYNXZKSzVyPUCuNFA3PjlizszN NHuxT5NUSU6JRWK=
MV-4-11 M1jXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm4UWxUUUN3ME2wMlAyPTh4IN88US=> NF:4SVdUSU6JRWK=
NKM-1 M3[5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDXOFVKSzVyPUCuNFE3QTlizszN MVrTRW5ITVJ?
ML-2 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMEG5PFMh|ryP NH\je|lUSU6JRWK=
BV-173 NVfi[IljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DsN2lEPTB;MD6wNlMyPCEQvF2= M3zhbXNCVkeHUh?=
RS4-11 NGDFb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMEK1PFch|ryP NHWz[opUSU6JRWK=
HL-60 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjSTWM2OD1yLkCyPVA5KM7:TR?= MofrV2FPT0WU
KY821 Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\qNGlEPTB;MD6wNlk4PSEQvF2= NGXmNYhUSU6JRWK=
ECC10 NH;YSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nhe2lEPTB;MD6wN|c6OiEQvF2= NU\BS5lrW0GQR1XS
NCI-H720 NEf1OFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\neGF2UUN3ME2wMlA1ODFzIN88US=> MX\TRW5ITVJ?
QIMR-WIL NWfkS3BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7KXm1kUUN3ME2wMlA1Ojh5IN88US=> MW\TRW5ITVJ?
KG-1 M1;WUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofxTWM2OD1yLkC0OFg3KM7:TR?= M1nkUXNCVkeHUh?=
TGW MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInmVWxKSzVyPUCuNFQ3OzNizszN Ml[5V2FPT0WU
ATN-1 NXf4No5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMES3N|Mh|ryP NF7N[m5USU6JRWK=
RH-18 MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwME[wOFgh|ryP MX\TRW5ITVJ?
EW-18 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluyTWM2OD1yLkC2PFQyKM7:TR?= NHnv[WNUSU6JRWK=
NB17 M4fROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;5RWJKSzVyPUCuNFcyOjRizszN MmrrV2FPT0WU
SK-NEP-1 M4XFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi3TWM2OD1yLkC3NlE{KM7:TR?= MkjiV2FPT0WU
P12-ICHIKAWA NGfCd4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHpd2NKSzVyPUCuNFc4PzhizszN M1;leHNCVkeHUh?=
KARPAS-45 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvyTWM2OD1yLkC3PFE2KM7:TR?= NVT1OZpiW0GQR1XS
EW-3 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHDfnZKSzVyPUCuNFgxPTNizszN MWfTRW5ITVJ?
NB13 Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HKZmlEPTB;MD6wPFIxOyEQvF2= MXXTRW5ITVJ?
NCI-H209 NF3UZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjB[GJjUUN3ME2wMlA5PzB2IN88US=> NWjFWZExW0GQR1XS
NCI-H1092 NHHU[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\5TWM2OD1yLkGwNlc2KM7:TR?= M2D2[nNCVkeHUh?=
NH-12 NHPKOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvWV3RKSzVyPUCuNVA4PDRizszN NHv2VW5USU6JRWK=
697 NFTDNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG3TWJ4UUN3ME2wMlExQDN7IN88US=> NIftRZRUSU6JRWK=
KE-37 NUjpSpVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\0dWlEPTB;MD6xNVM4KM7:TR?= MYfTRW5ITVJ?
MOLT-4 MnzqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q2WmlEPTB;MD6xOVE3QSEQvF2= MmG2V2FPT0WU
CHP-134 M4jWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTVTI9kUUN3ME2wMlE3OzB4IN88US=> MlfKV2FPT0WU
D-283MED MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vSUmlEPTB;MD6xO|Y5PiEQvF2= M3nuXXNCVkeHUh?=
LU-135 MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3nTWM2OD1yLkG4OVUzKM7:TR?= M1TJNnNCVkeHUh?=
LU-134-A Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3ERlI1UUN3ME2wMlE5PjdzIN88US=> NU\ncoQyW0GQR1XS
EM-2 M3zLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELMcJFKSzVyPUCuNVk6OThizszN NWnoWG9DW0GQR1XS
LU-139 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\3eGdZUUN3ME2wMlIxPDl6IN88US=> M4rvS3NCVkeHUh?=
ALL-PO M4TGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LjbWlEPTB;MD6yNVk5QCEQvF2= MVzTRW5ITVJ?
NB12 NVzGUGhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHa[m9KSzVyPUCuNlMyOTVizszN NYX6ZYd3W0GQR1XS
KP-N-YN MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMkO1O|Mh|ryP NVT3UVkxW0GQR1XS
BEN MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTrN3BrUUN3ME2wMlI{QTZ6IN88US=> MWHTRW5ITVJ?
HCC1569 M1GyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\n[2dKSzVyPUCuNlUyODZizszN NIjGSmFUSU6JRWK=
HuO9 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLJN3ZZUUN3ME2wMlI3PzF3IN88US=> NFK1TmtUSU6JRWK=
WM-115 NXfhVogxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTBwMke3N|gh|ryP M{TCSXNCVkeHUh?=
CCRF-CEM MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTBwM{O1Nlkh|ryP MojvV2FPT0WU
IST-SL1 MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHk[|I5UUN3ME2wMlM2OzR|IN88US=> NX\aPXd7W0GQR1XS
BE-13 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwM{[0OVkh|ryP MmCyV2FPT0WU
COR-L88 NFK5PIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPvbpBKSzVyPUCuN|Y2PCEQvF2= NEHOSW1USU6JRWK=
DOHH-2 NUm1SlVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G2S2lEPTB;MD60NVAzOyEQvF2= M4GyS3NCVkeHUh?=
A704 M1rtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwNEK2O{DPxE1? NXX0UmNFW0GQR1XS
KNS-81-FD NGfwboxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPFNndRUUN3ME2wMlQ1ODF5IN88US=> M4[4ZXNCVkeHUh?=
RPMI-8226 MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jMTGlEPTB;MD60OVY2OiEQvF2= M2\Tc3NCVkeHUh?=
TGBC24TKB NHLofWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNEW3O|gh|ryP MlrOV2FPT0WU
NCI-H1304 NFjkW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwNE[xOVch|ryP NH\5UJFUSU6JRWK=
MOLT-13 M2XyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNE[2NVMh|ryP MXTTRW5ITVJ?
EW-22 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH1XVlXUUN3ME2wMlQ3PjdzIN88US=> MlSxV2FPT0WU
MS-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwNE[5N|Mh|ryP MXzTRW5ITVJ?
RMG-I NX7odHdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7OTWM2OD1yLkS5OFY1KM7:TR?= MWfTRW5ITVJ?
NTERA-S-cl-D1 NWjwSWJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPOTZJKSzVyPUCuOVAxOTlizszN Mn;XV2FPT0WU
NCI-H1048 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\VTWM2OD1yLkWwPVU{KM7:TR?= MV;TRW5ITVJ?
SW1417 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fXd2lEPTB;MD61OVQ{QCEQvF2= MUHTRW5ITVJ?
DB M{nRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwNUewPEDPxE1? M3zLOnNCVkeHUh?=
MEG-01 NXHsboRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DrcmlEPTB;MD61PFMzKM7:TR?= NXvMTmV[W0GQR1XS
EW-13 M{TuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zldGlEPTB;MD61PFM1OSEQvF2= NHXvWG5USU6JRWK=
LAMA-84 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;PZmlEPTB;MD61PVIxPyEQvF2= NHPMbZlUSU6JRWK=
J-RT3-T3-5 Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HlOmlEPTB;MD62NFgxQCEQvF2= M3Kx[XNCVkeHUh?=
MOLT-16 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwNkWyOlQh|ryP M{PB[3NCVkeHUh?=
DU-4475 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\hVoZEUUN3ME2wMlY2PDJ5IN88US=> MVXTRW5ITVJ?
HAL-01 MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnnV5JwUUN3ME2wMlczPTR7IN88US=> MV7TRW5ITVJ?
RD MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7wTWM2OD1yLke1PFk6KM7:TR?= M{nSSnNCVkeHUh?=
OAW-28 NIDxcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXlPHJsUUN3ME2wMlc5OzdizszN MUfTRW5ITVJ?
HCC38 MlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn3[nYzUUN3ME2wMlgxOTlizszN MoS3V2FPT0WU
NMC-G1 NGj6NFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLHTWM2OD1yLkixNVIyKM7:TR?= MVLTRW5ITVJ?
EW-16 NYTtb3hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7NTWM2OD1yLkixN|I5KM7:TR?= M3Xic3NCVkeHUh?=
DU-145 M2LTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DKOmlEPTB;MD64PVkzOyEQvF2= NXXR[Yg5W0GQR1XS
HPAF-II M3nLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvETWM2OD1yLkmyOlI5KM7:TR?= MlTLV2FPT0WU
A427 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT4PJhKSzVyPUCuPVMxOjJizszN MXXTRW5ITVJ?
PA-1 M2C4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmyVplKSzVyPUCuPVU3PDJizszN Mk\MV2FPT0WU
OAW-42 NH;ydVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPNTIJKSzVyPUCuPVYyPDZizszN NW\4O3FiW0GQR1XS
L-428 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTFwMEGyOUDPxE1? M4nn[3NCVkeHUh?=
COLO-824 MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnhTWM2OD1zLkCxO|A5KM7:TR?= MXfTRW5ITVJ?
P30-OHK MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XNOWlEPTB;MT6wOFY5QCEQvF2= MnTIV2FPT0WU
NCI-H2170 NVfYe3BHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwME[yN{DPxE1? NX7EfJJkW0GQR1XS
HCC2998 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoCyTWM2OD1zLkC3NVM2KM7:TR?= MYfTRW5ITVJ?
NB14 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTFwMUO3OFgh|ryP NHjqZ|dUSU6JRWK=
TGBC1TKB M4fo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnaOYVKSzVyPUGuNVQyPTJizszN M{LtfnNCVkeHUh?=
KP-N-YS MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HETWlEPTB;MT6xOlI{PiEQvF2= NEDNR|RUSU6JRWK=
CAL-120 NIjkdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFqwSY1KSzVyPUGuNVY1OjlizszN Mm\lV2FPT0WU
SBC-1 NV\tTlBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvRTWM2OD1zLkG5NFU{KM7:TR?= M4P1bnNCVkeHUh?=
C32 NXH5PY5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwMUmwPFgh|ryP M{TOWXNCVkeHUh?=
HCC2157 NFXXU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvTTWM2OD1zLkG5OFk1KM7:TR?= Mlm0V2FPT0WU
COLO-792 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TzOGlEPTB;MT6yNFA4OSEQvF2= NXv2PWRGW0GQR1XS
ES7 NVvmZ3VET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTJVo5sUUN3ME2xMlI4QTVzIN88US=> MYPTRW5ITVJ?
HEL NGDCe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTKSpZKSzVyPUGuN|ExOjlizszN NWnwUpZnW0GQR1XS
ES4 MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG0SItLUUN3ME2xMlM1QTl6IN88US=> MY\TRW5ITVJ?
NCI-SNU-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rxfWlEPTB;MT6zOlU2PSEQvF2= MV;TRW5ITVJ?
MDA-MB-415 MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjafndJUUN3ME2xMlM5QDVizszN M{XqdHNCVkeHUh?=
NCI-H2342 NGHUWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;0TWM2OD1zLkSwNlY6KM7:TR?= M1j6TnNCVkeHUh?=
NB69 M2jLcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\HUmxKSzVyPUGuOFYzPzFizszN NEm1e2xUSU6JRWK=
D-247MG M2T6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv6TWM2OD1zLkWxNVIzKM7:TR?= MmHsV2FPT0WU
SCC-4 M13RO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXv[|dKSzVyPUGuOVk5QDdizszN MoLNV2FPT0WU
HuH-7 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSwTWM2OD1zLk[3Nlk{KM7:TR?= NWPQWZM5W0GQR1XS
A388 NVTn[5NUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwNki3NlQh|ryP NX\jV3BpW0GQR1XS
Calu-3 M{HPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnVfm0{UUN3ME2xMlcxPjl5IN88US=> NFLUVmpUSU6JRWK=
NCI-H1648 NYnVVZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvvUo1KSzVyPUGuO|E1OThizszN NWm1eI1[W0GQR1XS
NCI-H2052 NF;U[olIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGf5W4ZKSzVyPUGuO|IzODFizszN MoHUV2FPT0WU
Ramos-2G6-4C10 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTQfZVKSzVyPUGuO|M3PTZizszN M1KyNXNCVkeHUh?=
DEL NIHEXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDITWM2OD1zLke0OlkzKM7:TR?= NH73TmJUSU6JRWK=
SNU-423 MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwN{ixOVch|ryP Mn36V2FPT0WU
COR-L23 MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP5TWM2OD1zLke5PFc1KM7:TR?= NYPaZndRW0GQR1XS
OMC-1 M1zZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTFwOE[wNVYh|ryP NF\zfVlUSU6JRWK=
EW-11 NH7ZeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r3V2lEPTB;MT65OVY2PyEQvF2= MojIV2FPT0WU
HSC-3 NUnob|dwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XieWlEPTB;MT65OlM3PSEQvF2= M1HpZ3NCVkeHUh?=
MLMA NVT2NVM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LKfmlEPTB;MT65OlY4PyEQvF2= NHXFfFZUSU6JRWK=
RCM-1 M3LRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrpTWM2OD1{LkCwN|k6KM7:TR?= MXrTRW5ITVJ?
MFE-280 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfWTWM2OD1{LkCyPFQ5KM7:TR?= NUD5XYlCW0GQR1XS
ES8 MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NECwfoNKSzVyPUKuNlU1PzFizszN MWrTRW5ITVJ?
TE-11 NV;NSopCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrlTWM2OD1{LkK5OFc{KM7:TR?= NWfaSGt4W0GQR1XS
HuO-3N1 MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fN[GlEPTB;Mj60PFc5KM7:TR?= MYLTRW5ITVJ?
MHH-NB-11 NWX1VHdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwNUGxOVgh|ryP MYrTRW5ITVJ?
TGBC11TKB M1fHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK3[FNKSzVyPUKuOVc3QDFizszN M4\xcXNCVkeHUh?=
HOP-92 NFX4UoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvaWIdKSzVyPUKuOVg4PDNizszN NFKyeYVUSU6JRWK=
IGR-1 M3K5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq2PW5KSzVyPUKuOlIxOzVizszN MnS3V2FPT0WU
GOTO NYX3RY9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXtTWM2OD1{Lk[1N|c4KM7:TR?= NUHO[4Q1W0GQR1XS
NCI-H1650 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljmTWM2OD1{LkeyNlE2KM7:TR?= MU\TRW5ITVJ?
NCI-H1581 MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLvSJM1UUN3ME2yMlc6PjhzIN88US=> MUfTRW5ITVJ?
NCI-H2405 NYC1VlBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj5fFVYUUN3ME2yMlgzPzh{IN88US=> M3rkT3NCVkeHUh?=
U-118-MG NHLyOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXraNFFtUUN3ME2yMlk3PDlzIN88US=> MUDTRW5ITVJ?
DoTc2-4510 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwMEG0NVch|ryP MlXqV2FPT0WU
NCI-H596 NV3yNWZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDkTmdKSzVyPUOuNFQ6QTdizszN NInhXHlUSU6JRWK=
MPP-89 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwMEW2OlYh|ryP Mk\sV2FPT0WU
GCIY MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwMkC0PVEh|ryP NH7NSmpUSU6JRWK=
SW626 M16xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTNwMkS1OFMh|ryP NFHzb3FUSU6JRWK=
OCI-AML2 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jBbmlEPTB;Mz6zNVI4OiEQvF2= NFvLcndUSU6JRWK=
NBsusSR MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPLenJwUUN3ME2zMlM1QTN6IN88US=> M3jMSXNCVkeHUh?=
AN3-CA Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHpNlVPUUN3ME2zMlQ1OjN6IN88US=> NVyxdGJDW0GQR1XS
EFM-19 NEW5TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTNwNEizN|kh|ryP MYLTRW5ITVJ?
RVH-421 M3XuXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlSwTWM2OD1|LkW2PFc4KM7:TR?= M3LQTXNCVkeHUh?=
5637 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnWXZNKSzVyPUOuOlEyODNizszN M2TMVHNCVkeHUh?=
PANC-08-13 NInBOpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXJOWltUUN3ME2zMlY{PDd{IN88US=> MYPTRW5ITVJ?
H9 M2\hVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLtNGRKSzVyPUOuOlcyPDRizszN M{e0cHNCVkeHUh?=
KARPAS-299 NX\UW2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13wVGlEPTB;Mz62O|M3OSEQvF2= MVLTRW5ITVJ?
TE-5 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXXTWM2OD1|LkewO|A6KM7:TR?= MmG4V2FPT0WU
NOS-1 Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrUSVRKSzVyPUOuO|k5OzRizszN MWPTRW5ITVJ?
HH M{XhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTNwOEO4Olgh|ryP MWHTRW5ITVJ?
769-P MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH4TWM2OD1|Lki5OVEh|ryP MoLyV2FPT0WU
CHP-212 NGnNZ2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTNwOUK1OFkh|ryP M3vwdHNCVkeHUh?=
NCI-H82 NI[5PGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWftU3Q6UUN3ME2zMlk2QTN4IN88US=> MnPFV2FPT0WU
Mo-T NXP3cJF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojQTWM2OD12LkC0N|EzKM7:TR?= NULvVI1VW0GQR1XS
BB65-RCC NFS2OHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LWZWlEPTB;ND6wOFM6QSEQvF2= NEewPJpUSU6JRWK=
SW1990 NYH0N25GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOxd4FMUUN3ME20MlA2QTB6IN88US=> MXHTRW5ITVJ?
LK-2 M1;Q[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXNTWM2OD12LkGxNlk{KM7:TR?= MmniV2FPT0WU
ES5 M1v5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvGTWM2OD12LkGzPVg2KM7:TR?= NYDTWI5HW0GQR1XS
JVM-3 M2HHTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvjd|JyUUN3ME20MlE5OjJ{IN88US=> MkHKV2FPT0WU
RPMI-7951 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnzZZVIUUN3ME20MlIzPDF|IN88US=> MnnMV2FPT0WU
Calu-6 NYHNUI9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y4dWlEPTB;ND6yO|g5OSEQvF2= NWD5SFU3W0GQR1XS
LC-2-ad M2rZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu0NZlKSzVyPUSuNlk2PjhizszN NVPsXHpFW0GQR1XS
SW954 M2rUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTMWZpKSzVyPUSuNlk3PiEQvF2= MVjTRW5ITVJ?
H-EMC-SS M1W4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTBTWM2OD12LkOxPFMyKM7:TR?= M3zyeXNCVkeHUh?=
ES3 M3PqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;WNYJKSzVyPUSuN|U1PDFizszN MVjTRW5ITVJ?
no-11 M13ETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:0dI1bUUN3ME20MlM2PTV2IN88US=> Mo\rV2FPT0WU
LAN-6 NUXEN5pZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\NXINKSzVyPUSuOFUyQDlizszN MYPTRW5ITVJ?
FTC-133 M1zOV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG1TWM2OD12LkWzPVUh|ryP NWTNcYd7W0GQR1XS
8505C MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jIZWlEPTB;ND61OFI{KM7:TR?= NYDseodnW0GQR1XS
SW620 M{LOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfx[|VOUUN3ME20MlU4ODV5IN88US=> M3HPZXNCVkeHUh?=
BCPAP M4XLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT4SIR{UUN3ME20MlY{PDhzIN88US=> Mm\vV2FPT0WU
SK-LU-1 NF\2b21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS5TWM2OD12Lk[2NFg6KM7:TR?= NUXzUpExW0GQR1XS
NCI-H1623 NGrn[5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDtNVhkUUN3ME20MlcxOjJ6IN88US=> NGLjSVdUSU6JRWK=
C2BBe1 NWDlW5k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzmVJZMUUN3ME20Mlc1ODB6IN88US=> MXrTRW5ITVJ?
GP5d MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwN{izPFgh|ryP MnPtV2FPT0WU
NB6 M{Hr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTPTWM2OD12Lki2NlA1KM7:TR?= NYHPbXdXW0GQR1XS
MDA-MB-157 NVTNe49ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXj[plKSzVyPUSuPFg4PiEQvF2= NWLH[5M6W0GQR1XS
UMC-11 NH7uN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnIWFFKSzVyPUSuPFg6PjRizszN MWrTRW5ITVJ?
HCC1419 NF7aPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTEZ243UUN3ME20MlkxODZ|IN88US=> M1LNZnNCVkeHUh?=
NCI-H2029 NFf1bXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TtTWlEPTB;ND65OFE5PSEQvF2= Mnr1V2FPT0WU
LXF-289 Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrlUFZKSzVyPUWuNFM4OTlizszN NUXOeYg5W0GQR1XS
KINGS-1 NUjLNY13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjMeXlZUUN3ME21MlA4PzR2IN88US=> M4nRenNCVkeHUh?=
HD-MY-Z NW\ObGtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW4dFdSUUN3ME21MlI{QTZ7IN88US=> MWPTRW5ITVJ?
ESS-1 NGjIRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe4blY3UUN3ME21MlI2PTl5IN88US=> NYjJTYc2W0GQR1XS
GI-1 Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jjRWlEPTB;NT6yO|kzPiEQvF2= NHuzbGtUSU6JRWK=
RPMI-2650 NH\jO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHTN3dKSzVyPUWuN|YyPiEQvF2= NHLyZ2VUSU6JRWK=
IA-LM Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTyT|hKSzVyPUWuN|k5PzFizszN MXzTRW5ITVJ?
KP-4 NXmzU3B1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzUdnRKSzVyPUWuOFY{OzRizszN NEK5O3RUSU6JRWK=
G-402 M1i5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTVwNUG4OlUh|ryP NGDyS4hUSU6JRWK=
OS-RC-2 M2O5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTVwNUK2NFQh|ryP NWHNcZcyW0GQR1XS
NCI-H1155 M1Tu[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1roTmlEPTB;NT61OFk2PSEQvF2= NUn5bGRYW0GQR1XS
OE19 NFrlZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLYenhTUUN3ME21MlY5PjJ2IN88US=> M1jXTnNCVkeHUh?=
U-2-OS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17uWWlEPTB;NT64PVAyOyEQvF2= NHfNPXhUSU6JRWK=
SCC-15 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHFXnhKSzVyPUWuPVM3PjJizszN NVPrNXBTW0GQR1XS
NCI-H630 MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XCSmlEPTB;NT65PVQxPCEQvF2= NWi1enU6W0GQR1XS
PFSK-1 NF3EV2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3aTWM2OD14LkC1NlU6KM7:TR?= MYfTRW5ITVJ?
NCI-H1770 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jkPGlEPTB;Nj6yNFg4PCEQvF2= NIDNdlJUSU6JRWK=
SK-MEL-3 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTZwNEK5NVUh|ryP MmTvV2FPT0WU
LB1047-RCC NFfOUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;ieJk{UUN3ME22MlQ4PjJ3IN88US=> MUTTRW5ITVJ?
NCI-H446 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHMTWM2OD14Lk[yPVI2KM7:TR?= MX3TRW5ITVJ?
SW780 M3;abWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj6N4JOUUN3ME22MlcxOTh3IN88US=> M4HXbnNCVkeHUh?=
NEC8 MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OyS2lEPTB;Nj63OlY{KM7:TR?= M3TyOnNCVkeHUh?=
NOMO-1 NGH5W|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfWXI1KSzVyPU[uO|gyOTFizszN NF;NV|ZUSU6JRWK=
COLO-668 NYjoSXJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTZwOESzPFch|ryP MnTTV2FPT0WU
MC116 MlTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTZwOUO4PVch|ryP M4jiXXNCVkeHUh?=
HCC1937 NWPTeIIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nvT2lEPTB;Nj65PVI2OSEQvF2= MnXRV2FPT0WU
NCI-N87 M3jsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjNZ4N4UUN3ME23MlE6Ojl|IN88US=> NGTnZWVUSU6JRWK=
COLO-320-HSR NVLJbJVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInxd3dKSzVyPUeuNlI4OzhizszN Ml71V2FPT0WU
HCC1806 NF;BPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO5WYRKSzVyPUeuNlYxPDRizszN MXHTRW5ITVJ?
OVCAR-3 NGLsfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfMTWM2OD15LkOzNFM5KM7:TR?= MXPTRW5ITVJ?
NUGC-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7B[29KSzVyPUeuN|k3QTRizszN MX7TRW5ITVJ?
SW1783 Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHkOWNIUUN3ME23MlQ{OTd3IN88US=> M3S4fHNCVkeHUh?=
GCT MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL6TWM2OD15LkW2PVA3KM7:TR?= MnL2V2FPT0WU
NCI-H2126 M{HTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTdwN{O2NlUh|ryP Ml:5V2FPT0WU
MEL-HO NFnYdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKxemxKSzVyPUeuO|cxPTRizszN NFnSe4tUSU6JRWK=
CAPAN-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTdwN{ezOVch|ryP MoqwV2FPT0WU
SW756 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn2UGFJUUN3ME23Mlc5OzN|IN88US=> M{e1XXNCVkeHUh?=
SKG-IIIa MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjWeJFKSzVyPUeuPFE5QTJizszN MX;TRW5ITVJ?
HCE-T NHr1V25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTdwOEe3PFMh|ryP NIPa[5dUSU6JRWK=
Ca-Ski MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTdwOUmzPFMh|ryP MXjTRW5ITVJ?
COLO-684 M4r1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jJ[2lEPTB;OD6wNVgyQCEQvF2= NUXLeoc3W0GQR1XS
KYSE-70 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHCWHRKSzVyPUiuNFc4OjlizszN MYHTRW5ITVJ?
TI-73 MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTYWmRKSzVyPUiuNlU5PTFizszN M17WRXNCVkeHUh?=
BT-20 M{n0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPhSINDUUN3ME24MlI3ODV{IN88US=> NG\pe2VUSU6JRWK=
MHH-ES-1 MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfwOnRlUUN3ME24MlUyQDN2IN88US=> NIG2NVRUSU6JRWK=
TE-12 Ml3rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPVSVZ4UUN3ME24MlU6QTNzIN88US=> NUjOSGV4W0GQR1XS
YH-13 NXW5TGtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7sTWM2OD16Lk[xNFA5KM7:TR?= NETQWIRUSU6JRWK=
SF126 NF:2WIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRThwOEO4OlUh|ryP MXjTRW5ITVJ?
J82 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRThwOUCwN|gh|ryP NH2ze|NUSU6JRWK=
RCC10RGB MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq3e5ViUUN3ME24Mlk6PTZzIN88US=> MXjTRW5ITVJ?
SK-UT-1 NYT2fmJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTUTWM2OD17LkC0PVQ2KM7:TR?= Ml[2V2FPT0WU
LB2241-RCC M3TlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXtU|RKSzVyPUmuNVkyOzdizszN NILHenFUSU6JRWK=
LB996-RCC MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELoe|BKSzVyPUmuNVk5QSEQvF2= NYfwXGl{W0GQR1XS
EPLC-272H MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon1TWM2OD17LkO3OlU4KM7:TR?= M3\k[HNCVkeHUh?=
CTV-1 MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUW0ZWI6UUN3ME25MlU3PTN{IN88US=> MYrTRW5ITVJ?
HSC-2 NH7BNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXXWG02UUN3ME25MlU4PTVizszN NYnUTowzW0GQR1XS
SK-MEL-28 NIXLeGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TaVmlEPTB;OT62NVg6OyEQvF2= MYfTRW5ITVJ?
MMAC-SF MkW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTlwNki3OUDPxE1? NIT3N5lUSU6JRWK=
CP50-MEL-B NYnScWZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYThOZhPUUN3ME25Mlc2Pzh{IN88US=> M1:4dnNCVkeHUh?=
HT-1080 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX2xc|VnUUN3ME25Mlc4PzN7IN88US=> NVW0S4M1W0GQR1XS
HEC-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK3cJRKSzVyPUGwMlM{PTJizszN MYPTRW5ITVJ?
AGS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH1TWM2OD1zMD6zO|Qh|ryP Mn7PV2FPT0WU
GAMG MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLoZnVpUUN3ME2xNE42OTZ{IN88US=> NFX6ZW9USU6JRWK=
SW48 NHTmeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLh[oJKSzVyPUGwMlUyQDlizszN M{XQWXNCVkeHUh?=
U031 M{[0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHmeHVKSzVyPUGwMlU6ODhizszN MXfTRW5ITVJ?
OVCAR-5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDIemxlUUN3ME2xNE43PDJ7IN88US=> NWW4blU1W0GQR1XS
SF295 NYTzN5h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr3XlY4UUN3ME2xNE43PzB2IN88US=> NXv1ZVFIW0GQR1XS
BHT-101 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7tcWZIUUN3ME2xNE44OTd5IN88US=> M131fnNCVkeHUh?=
VMRC-RCZ NEX1SWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjFcXFKSzVyPUGxMlMzODFizszN MojRV2FPT0WU
ACHN NUixc45ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTDNYRKSzVyPUGxMlQzOTFizszN MXfTRW5ITVJ?
NCI-H526 NGra[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFzLkWwOFMh|ryP NFfKfmdUSU6JRWK=
MN-60 NVv1Sm41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFzLkWzPUDPxE1? NYXDZphbW0GQR1XS
NCI-H2291 MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j6Z2lEPTB;MUGuOVQ3PiEQvF2= Mnq2V2FPT0WU
SCC-25 NEe5eI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDJOnE6UUN3ME2xNU44PTV4IN88US=> NYrGPFc4W0GQR1XS
SK-MEL-2 NFrKPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXTTWM2OD1zMT63OlM4KM7:TR?= NWjHS3c{W0GQR1XS
SN12C M3rS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHZTWM2OD1zMT65N|U2KM7:TR?= NV\HeJpFW0GQR1XS
NCI-H69 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3BcJg{UUN3ME2xNk41OjN2IN88US=> M{LzVnNCVkeHUh?=
ME-180 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfBWmtKSzVyPUGyMlcxPTRizszN MoTDV2FPT0WU
MC-IXC NV3G[3VuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zhSWlEPTB;MUKuO|UyQCEQvF2= MWjTRW5ITVJ?
NCI-H2347 M1fLdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;1TWM2OD1zMj63OlE1KM7:TR?= NFHQ[ZhUSU6JRWK=
M059J NHHJXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF{Lke3Nlch|ryP NYPWUGlHW0GQR1XS
A2058 M{TmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXBN4RKSzVyPUGyMlg3QDFizszN NGrld45USU6JRWK=
VA-ES-BJ NIruSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HNVWlEPTB;MUKuPFc5PSEQvF2= NUjIbJFQW0GQR1XS
Ca9-22 NGXFcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXBTWM2OD1zMj65OFUyKM7:TR?= MkfmV2FPT0WU
KNS-42 M2TW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS2VohKSzVyPUGyMlk6QDRizszN MonHV2FPT0WU
LoVo MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm5OmdPUUN3ME2xN{4zOzF|IN88US=> NUfPVG04W0GQR1XS
AM-38 M2L6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP0XpE2UUN3ME2xN{4zPTZ4IN88US=> MlPZV2FPT0WU
NB5 M1PKe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF|LkO3OVIh|ryP NH3vdnVUSU6JRWK=
L-363 MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\JTmlEPTB;MUOuOFA{OyEQvF2= M2jieHNCVkeHUh?=
SK-MEL-30 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzFWmU6UUN3ME2xOE4xPjR3IN88US=> MVXTRW5ITVJ?
NCI-H1563 NHPrbXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S2V2lEPTB;MUSuOlA{QSEQvF2= MWHTRW5ITVJ?
NCI-H2228 NF\CUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDCeG5JUUN3ME2xOE43ODd5IN88US=> NGPvNppUSU6JRWK=
MFM-223 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF3LkG4NVMh|ryP NFu1[o1USU6JRWK=
LB831-BLC NXfTTHJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHqO|JKSzVyPUG1MlI4PjdizszN M1LYWHNCVkeHUh?=
SW872 M3:wbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF3LkOwPFYh|ryP M2niV3NCVkeHUh?=
NCI-H522 M3foO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTCRYk5UUN3ME2xOU4{OzB4IN88US=> NHLSdYxUSU6JRWK=
EW-1 NEHBZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF3LkW0OlIh|ryP MorVV2FPT0WU
HN NXn1SZlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD6fmRKUUN3ME2xOU42QTR{IN88US=> MmHQV2FPT0WU
SW837 M{jkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nveGlEPTB;MUWuO|g1PyEQvF2= Ml;qV2FPT0WU
SCC-9 NIrqfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vueWlEPTB;MUWuPFEyPCEQvF2= MVzTRW5ITVJ?
MKN7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOyTWM2OD1zNT65O|MzKM7:TR?= NFzifGZUSU6JRWK=
KYSE-410 MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\RU2lEPTB;MU[uOVkyKM7:TR?= MoPEV2FPT0WU
SK-N-DZ NYrnO3ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF4Lk[xNVYh|ryP NEm0ZWhUSU6JRWK=
COR-L105 Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrwcZNzUUN3ME2xOk43PTJ6IN88US=> NXnVNGdqW0GQR1XS
LB2518-MEL NULhcVZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjKdHJKSzVyPUG2Mlg{QDlizszN MoKyV2FPT0WU
OVCAR-4 M4rjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF4Lki4OlIh|ryP MUXTRW5ITVJ?
TK10 MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLCU|hiUUN3ME2xOk46PDd|IN88US=> M4DJcnNCVkeHUh?=
KNS-62 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTF4Lkm3O|ch|ryP M1TqUnNCVkeHUh?=
RPMI-8866 M1PBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHDUZByUUN3ME2xO{4yPzN{IN88US=> MYPTRW5ITVJ?
HuP-T4 MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjVW3ZKSzVyPUG3MlI1QTVizszN MkPvV2FPT0WU
CGTH-W-1 MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLSRnBKSzVyPUG3MlUzOTlizszN MXvTRW5ITVJ?
T-24 NILW[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjqbHNKSzVyPUG3MlU{PDdizszN M3;1NnNCVkeHUh?=
HT-3 NIO1U3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzUTWM2OD1zNz61PVE1KM7:TR?= MlvNV2FPT0WU
KS-1 NG\oTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4P4SmlEPTB;MUeuOlc{KM7:TR?= NEnnblNUSU6JRWK=
NCI-H1792 NIiw[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF5Lke5PEDPxE1? NHn5SIhUSU6JRWK=
ABC-1 NVfFOIVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK0RXdKSzVyPUG3MlgyPDFizszN NUfhZ4RQW0GQR1XS
BPH-1 NGGxOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mon6TWM2OD1zOD6xOlg2KM7:TR?= MWnTRW5ITVJ?
A431 NE\Wd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYS4NmJXUUN3ME2xPE41OTJ5IN88US=> NYjwb5dVW0GQR1XS
T98G Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXtSZo3UUN3ME2xPE42OTV5IN88US=> NHzIbZVUSU6JRWK=
BHY M{D6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvyNY9KSzVyPUG4Mlg3QSEQvF2= NGnzOZdUSU6JRWK=
Capan-2 NGDNOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTF6LkmwO|gh|ryP MnnvV2FPT0WU
MDA-MB-175-VII NWnhSllIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfJeW5VUUN3ME2xPE46OjB7IN88US=> M4fFcXNCVkeHUh?=
CAL-27 M3vQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjR[3BKSzVyPUG5MlA1QDdizszN MoPIV2FPT0WU
AsPC-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\RfmlEPTB;MUmuPFY2PyEQvF2= MmPUV2FPT0WU
KU812 NYfpUmltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC4XIx{UUN3ME2xPU46PTd|IN88US=> MnfEV2FPT0WU
NCI-H441 M4TCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJyLkCwNUDPxE1? MVjTRW5ITVJ?
Mewo NEjldnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17pfGlEPTB;MkCuNVI5QCEQvF2= NUnCc3hIW0GQR1XS
SK-MEL-24 Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLEZoQzUUN3ME2yNE4yPDd5IN88US=> NWfTWZlZW0GQR1XS
NCI-H727 NVTGRWtxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4roPWlEPTB;MkCuNlcxPCEQvF2= MX7TRW5ITVJ?
EKVX M3G4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW0NVBKSzVyPUKwMlYxPiEQvF2= M2WyUHNCVkeHUh?=
RT-112 M1fYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuzNllKUUN3ME2yNE43OTJ{IN88US=> M{PvUnNCVkeHUh?=
CAMA-1 NEDsNXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33xdmlEPTB;MkCuPVgxOyEQvF2= NGHnWGhUSU6JRWK=
SW900 NVKzO|k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PqOWlEPTB;MkGuNFE1QSEQvF2= M1G5T3NCVkeHUh?=
NCI-H23 NWH0bGNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WzOmlEPTB;MkGuNVI4PyEQvF2= NEK1NJNUSU6JRWK=
SK-PN-DW NH[yfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjt[YJ[UUN3ME2yNU4yPjR7IN88US=> NYG1OJhDW0GQR1XS
BB30-HNC NFfIZ4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTJzLkK3OFUh|ryP MljNV2FPT0WU
VM-CUB-1 NEXhU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXFdnFKSzVyPUKxMlM2OzZizszN NV;KPXBFW0GQR1XS
IST-MEL1 NGrNdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPFVmc6UUN3ME2yNU4{Pjl{IN88US=> NUnwcpZjW0GQR1XS
CTB-1 NGjnem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzwTWM2OD1{MT60O|U2KM7:TR?= NF75Z4VUSU6JRWK=
LCLC-103H MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\ub2tKSzVyPUKyMlE2QDJizszN MXTTRW5ITVJ?
PANC-03-27 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDvTWM2OD1{Mj61NVY6KM7:TR?= NECwW5NUSU6JRWK=
HTC-C3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorMTWM2OD1{Mj61OVU2KM7:TR?= NXTQeHJNW0GQR1XS
TE-8 NWjuXnJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJ|LkK1OlUh|ryP MmrHV2FPT0WU
NCI-H292 M2i0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHhc|VKSzVyPUK1MlM2OzZizszN MUPTRW5ITVJ?
COLO-680N MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ3Lk[zNlkh|ryP NYLBV|YyW0GQR1XS
KYSE-520 MknNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jOTWlEPTB;MkWuOlQ1KM7:TR?= MV7TRW5ITVJ?
NB10 NEG1U4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j5PGlEPTB;Mk[uN|EyPyEQvF2= M3vGfXNCVkeHUh?=
NCI-H661 NHizTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DNOmlEPTB;Mk[uOFcyOyEQvF2= MnrnV2FPT0WU
GMS-10 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT3TWM2OD1{Nj64OlM5KM7:TR?= NXPQWGR[W0GQR1XS
NCI-H2122 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ4Lkm5PVgh|ryP NE\rOFdUSU6JRWK=
OVCAR-8 NGHMSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPyTlhKSzVyPUK3MlA3OzhizszN NUfPWHpQW0GQR1XS
DJM-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:2fmlEPTB;MkeuNVQ2PCEQvF2= NUX3TnduW0GQR1XS
UACC-893 M{PkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfXTWM2OD1{Nz65PFc5KM7:TR?= M13uNXNCVkeHUh?=
C8166 M1HrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D2NmlEPTB;MkiuOlk{QCEQvF2= NYrUPXNNW0GQR1XS
NCI-H1693 NIrTRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjF[pJtUUN3ME2yPE43QTd3IN88US=> M1:5bXNCVkeHUh?=
TYK-nu NUmxNGYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLnV|FKSzVyPUOwMlA{PDVizszN NEL5WVJUSU6JRWK=
SW1710 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HreGlEPTB;M{CuNVI3KM7:TR?= NInzOFRUSU6JRWK=
A375 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTNyLkOyOFMh|ryP M{\FVHNCVkeHUh?=
HMV-II NIXxO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XRXWlEPTB;M{GuN|U6OiEQvF2= M37QOXNCVkeHUh?=
NCI-H2087 NV65dVJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTNzLk[zOVIh|ryP NUTD[HBGW0GQR1XS
CAL-54 NEPOZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrZTWM2OD1|MT63NlQyKM7:TR?= M{i4R3NCVkeHUh?=
HCC70 NGXOVodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T0SGlEPTB;M{KuNVM5PyEQvF2= NGns[XlUSU6JRWK=
ES1 NXLsRpR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTN{LkOwOlIh|ryP M4TESXNCVkeHUh?=
NCI-H1355 NF71SpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XLfWlEPTB;M{OuNlA1KM7:TR?= M1zJXnNCVkeHUh?=
CFPAC-1 NUHXO2puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnLbHdbUUN3ME2zN{4zOzN{IN88US=> NV\p[WlqW0GQR1XS
MKN28 NVjlNZJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTN|LkO4NFkh|ryP MXPTRW5ITVJ?
HDLM-2 NYCxfVRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIq5O3NKSzVyPUOzMlY6OzFizszN MVLTRW5ITVJ?
PANC-10-05 NUjncJBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e1XGlEPTB;M{SuNVAyPCEQvF2= NFv6WG1USU6JRWK=
SAS MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnOzTWM2OD1|ND60OVY2KM7:TR?= MYTTRW5ITVJ?
HCC1395 NYPse2NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CxU2lEPTB;M{SuO|E5PiEQvF2= Mn31V2FPT0WU
8305C M1qyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTN3Lki0NVUh|ryP MoLOV2FPT0WU
KM12 NGXqXWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN4Lke1OFch|ryP NGnDfJlUSU6JRWK=
SW1116 NGDtVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLwTWM2OD1|Nz61PVkzKM7:TR?= MYPTRW5ITVJ?
SK-MEL-1 NHvPNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\MZmlEPTB;M{iuN|M5QSEQvF2= NGPadoRUSU6JRWK=
HCC2218 M{fi[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTN6Lk[1NVkh|ryP MVzTRW5ITVJ?
T84 Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXhTWM2OD1|OD63OFA6KM7:TR?= M4XXZnNCVkeHUh?=
ETK-1 M120dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDuWHFKSzVyPUO5MlAzOiEQvF2= M17K[HNCVkeHUh?=
COLO-800 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHKTWM2OD1|OT6zPFY5KM7:TR?= MYTTRW5ITVJ?
CAL-12T NXq5XGxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonVTWM2OD1|OT61NlgyKM7:TR?= M{POV3NCVkeHUh?=
ACN NXHNVm1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTRyLkS5NVEh|ryP MXTTRW5ITVJ?
SJSA-1 MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPHTWM2OD12MT6xOVk3KM7:TR?= M4TvOHNCVkeHUh?=
PSN1 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTRzLkG3OFkh|ryP M3vQcHNCVkeHUh?=
D-566MG M{O1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWraeItSUUN3ME20NU4zODh4IN88US=> NWm1dYNpW0GQR1XS
EGI-1 NYDVUZk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjBe5JKSzVyPUSyMlQzQCEQvF2= NGTFdFlUSU6JRWK=
A204 M2LCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTR{Lk[zPFgh|ryP NFy1N3lUSU6JRWK=
Saos-2 NHnzWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX4R4lCUUN3ME20Nk45OzZ7IN88US=> M1zzNXNCVkeHUh?=
SNU-C2B Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXiTWM2OD12Mz62PFc5KM7:TR?= MnK3V2FPT0WU
HLE M2PQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nHZmlEPTB;NESuNFg2PiEQvF2= MX3TRW5ITVJ?
SW1463 M2PxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TaeGlEPTB;NESuPVk4OSEQvF2= M1n4WnNCVkeHUh?=
DSH1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPuNno2UUN3ME20OU4xODN|IN88US=> NYnE[4VzW0GQR1XS
MCF7 Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\qbVJFUUN3ME20OU42ODVzIN88US=> MmrMV2FPT0WU
K5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HMW2lEPTB;NEWuPVQxPSEQvF2= NIXKbXpUSU6JRWK=
NCI-H358 M{DFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTR5LkKxOUDPxE1? NITYXoRUSU6JRWK=
NCI-H2030 NIHFdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn6wTWM2OD12Nz6yN|c1KM7:TR?= NVXWPVVKW0GQR1XS
SW948 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3BTWM2OD12Nz60OlQh|ryP MUPTRW5ITVJ?
BALL-1 M4XJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTR5Lk[xOlgh|ryP NUTwPGI4W0GQR1XS
TE-9 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj4T4xZUUN3ME20O{46PThzIN88US=> NHTJ[5ZUSU6JRWK=
SK-N-FI MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTR6LkCzOVgh|ryP Mn6xV2FPT0WU
KALS-1 NVfG[3MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr3dXpiUUN3ME20PE4yOjh7IN88US=> M16zTnNCVkeHUh?=
HO-1-N-1 NFH0Z5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rF[GlEPTB;NEiuO|Q1PSEQvF2= NXP0RnZCW0GQR1XS
NCI-H2452 NWXNVlVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1[5RWlEPTB;NEmuNVE2OiEQvF2= MlXEV2FPT0WU
OC-314 M4CyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfNXJhKSzVyPUS5MlY5OzRizszN M4jkN3NCVkeHUh?=

... Click to View More Cell Line Experimental Data
In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]
+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]
+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]
+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing. 		7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3
CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02143401 Recruiting Cirrhosis|Hepatitis B Infection|Hepatitis C Infection|Metastatic Malignant Solid Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Malignant Solid Neoplasm|Refractory Malignant Neoplasm|Stage IV Hepatocellular Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 7 2014 Phase 1
NCT02079740 Recruiting Advanced Malignant Solid Neoplasm|KRAS Gene Mutation|Metastatic Malignant Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Malignant Solid Neoplasm|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer AJCC v7|Stage III Lung Cancer AJCC v7|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IIIA Colorectal Cancer AJCC v7|Stage IIIB Colorectal Cancer AJCC v7|Stage IIIC Colorectal Cancer AJCC v7|Stage IV Colorectal Cancer AJCC v7|Stage IV Lung Cancer AJCC v7|Stage IV Pancreatic Cancer AJCC v6 and v7|Stage IVA Colorectal Cancer AJCC v7|Stage IVB Colorectal Cancer AJCC v7|Unresectable Malignant Neoplasm National Cancer Institute (NCI) March 7 2014 Phase 1|Phase 2
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2
NCT02520778 Recruiting EGFR Activating Mutation|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.G719X|EGFR NP_005219.2:p.L858R|EGFR NP_005219.2:p.L861Q|EGFR NP_005219.2:p.T790M|Stage III Non-Small Cell Lung Cancer AJCC v7|Stage IIIA Non-Small Cell Lung Cancer AJCC v7|Stage IIIB Non-Small Cell Lung Cancer AJCC v7|Stage IV Non-Small Cell Lung Cancer AJCC v7 National Cancer Institute (NCI) March 31 2016 Phase 1
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Small Cell Lung Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 28 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

selleck catalog

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

  • Selective Bcl-2 Inhibitor

    ABT-199 (GDC-0199) : Bcl-2-selective, Ki<0.01 nM.

  • Bcl-2 Inhibitor in Clinical Trial

    Obatoclax Mesylate (GX15-070) : Phase II for leukemia, lymphoma, myelofibrosis, and mastocytosis.

  • Newest Bcl-2 Family Activator

    BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • Classic Bcl-2 Inhibitor

    ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

  • A-1210477 New

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838) New

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

  • Sabutoclax

    Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID